On June 18, 2025 GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, reported the initial closing of an $8.0 million Series C financing (Press release, GeneCentric Therapeutics, JUN 18, 2025, View Source [SID1234653996]). The proceeds will be used to launch and commercialize GeneCentric’s GenomicsNext, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample. This novel gene expression platform will accelerate the growth of GeneCentric’s pipeline of predictive response signatures for oncology therapeutics development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The funding round was led by Hatteras Venture Partners, with current participation from existing investors IAG Capital Partners, Alexandria Venture Investments, and Labcorp. The financing is expected to provide a cash runway for GeneCentric through 2026.
"While we see many new liquid biopsy companies seeking funding, GeneCentric has the most compelling opportunity we have identified," said Clay Thorp, General Partner, Hatteras Ventures Partners. "GenomicsNext has the potential to become the ‘decoder ring’ for translating a broad array of tissue-based biomarkers into liquid biopsy formats. This could transform how patients are identified and how disease and treatments are monitored."
"With a single blood sample from a cancer patient, our GenomicsNext liquid biopsy platform can determine the gene expression of drug target genes, molecular subtypes, and predictive gene signatures, in addition to mutations and fusions," said Mike Milburn, PhD, President and CEO of GeneCentric Therapeutics. "We believe our unique fragmentomics technology will become the best-in-class application for yielding greater insights and biomarker coverage from liquid biopsies to better aid diagnosis and treatment selection for patients. We are grateful for the enthusiasm and support of our investors and expect to make the GenomicsNext platform commercially available as a powerful research tool for biopharmaceutical companies in 2025."
About GenomicsNext
While liquid biopsy enables the diagnosis or analysis of tumors using a blood or fluid sample rather than a tissue biopsy, it currently focuses on measuring mutations in genes and not their expression. This narrow focus limits its utility, because important measures including molecular subtypes and common biomarkers for targeted therapy, such as HER2 or antibody-drug conjugates, are not measured by most assays, potentially delaying diagnosis and administration of life-saving oncology therapeutics.
Building on over a decade of expertise with gene expression, GeneCentric developed ExpressCT, a breakthrough technology that measures gene expression using information embedded in ctDNA, to provide a more complete liquid biopsy solution for precision oncology. The company will apply this technology through GenomicsNext, its integrated platform for comprehensive liquid biopsy testing. Once launched, the platform will simultaneously provide high-fidelity DNA variants and gene expression information.
"We’ve known that gene expression is a powerful diagnostic adjunct to traditional DNA alterations, but unlike tumor tissue profiling today, gene expression measurement is largely missing from liquid biopsy assays," said Kirk Beebe, PhD, Chief Scientific Officer of GeneCentric. "The GenomicsNext platform delivers a dramatic step change in the diagnostic utility of ctDNA-based liquid biopsies by ushering in this dimension."